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Abstract
Background: Our first trial on radiotherapy for painful heel spur published in 2012 comparing the analgesic effect
of a standard dose (6 × 1.0Gy within three weeks) to that of a very low one (6 × 0.1Gy within three weeks) resulted
in a highly significant superiority of the standard dose arm. In the meantime, experimental data have shown that
lower single doses in the range of 0.5 – 0.7Gy might be even more effective than the current standard dose of
1.0 Gy. Therefore, we conducted a second trial comparing the analgesic effect of standard single doses of 1.0Gy to
that of low single doses of 0.5Gy using uniform total doses of 6Gy.
Patients and methods: One hundred twenty-seven patients were randomized to receive radiation therapy either
with a total dose of 6.0Gy applied in 6 fractions of 1.0Gy twice weekly (standard dose) or with the same total dose
applied in 12 fractions of 0.5Gy three times weekly (experimental dose). In all patients lateral opposing 6MV photon
beams were used. The results were measured using Visual analogue scale (VAS), Calcaneodynia score (CS) and SF-12
health survey. The first phase of this trial ended after a three months’ follow-up; it will be continued up to 48 weeks.
Results: Nine patients had to be excluded after randomization either due to the withdrawal of informed consent to
radiotherapy by the patients or radiotherapy with an incorrect dosage. The groups were comparable concerning
biographical and disease data. The mean calcaneodynia score (CS) was higher in the experimental group (p = 0.002).
After three months’ follow-up, we saw a very favorable pain relief in both arms (decline of VAS score: standard arm 42
points, experimental arm 44 points (n.s.), but we did not notice any statistically significant difference between the arms
neither concerning the pain parameters nor the quality of life parameters. No relevant acute side effects were recorded.
Conclusions: Favorable laboratory results could not be translated into an enhanced pain relief in our patients. This trial
was terminated after the interim analysis (127 patients randomized). Further trials will be necessary to explore the best
fractionation schedule.
This trial has been approved by the expert panel of the DEGRO as well as by the Ethics committee of the Saarland
Physicians’ chamber.
Trial registration: Current trial registration at German Clinical Trials Register with the number DRKS00004458
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Background
The painful heel spur or plantar fasciitis was first de-
scribed by Plettner [1] summarizing radiological find-
ings of exostoses situated at the plantar part of the
calcaneus or at the insertion point of the plantar apo-
neurosis. Various authors give values for the incidence
of 8-88 % in an unselected population [2–4]. Described
risk factors are old age, obesity and foot or leg deform-
ities. Further data concerning histology, symptoms and
alternative therapy methods are given elsewhere [5, 6].
Our first randomized trial on plantar fasciitis [5] com-
paring the analgesic effect of a standard dose (1.0Gy two
times a week up to a total dose of 6Gy) to that of a very
low dose (0.1Gy two times a week up to a total dose of
0.6Gy) resulted in a highly significant superiority of the
standard dose. Thus, to our opinion the analgesic effect
of low-dose radiotherapy for painful heel spur could be
confirmed.
In the last 15 years, in-vitro data have shown that sin-
gle doses in the range 0.5-0.7Gy might be even more ef-
fective than higher ones. Roedel et al. published in 2002
that single doses of 0.3-0,5 Gy lead to a local maximum
of apoptosis in macrophages and a reduced E-selectin-
presentation on endothelium cells combined with an en-
hanced expression of TGFß1 [7]. Hildebrand could also
show in vitro that depending on modulation of cytokine-
stimulated E-selectin-presentation leukocytes could less
adhere to endothelium especially with single doses of 0.3-
0.6 Gy. This finding also underlines the anti-inflammatory
effect of low-dose therapy [8]. Additionally, Gaipl et al.
(2009) revealed a maximum of activity-induced cell death
in polymorphnuclear cells by the use of single doses of
0.3 Gy in radiotherapy [9]. Further anti-inflammatory ef-
fects of low-dose radiotherapy seem to be a reduced CCL-
20-chemokine-expression, a reduced adhesion of granulo-
cytes to endothelium cells and an enhanced activity of
AP-1 DNA ligation strength [10]. An actual review article
stresses the increased expression of the X-linked inhibitor
of apoptosis and TGFß1 and the reduced expression of E-
and L-selectin, Interleukin-1 and CCL20 through macro-
phages and polymorphnuclear cells using single doses be-
tween 0.5 and 0.7 Gy [11]. Another review article shows
additionally high levels of hemioxigenase 1 (HO-1) and
heat shock protein 70 (HSP 70) at a maximum using sin-
gle doses of 0.5 Gy [12].
Thus, we conducted a second clinical prospective ran-
domized multicenter trial in order to compare the anal-
gesic effect of a (to that time) standard single dose of
1Gy to that of a lower dose of 0.5Gy keeping the total
dose constant.
Patients and methods
In this prospective multicenter randomized trial patients
were included if meeting the following criteria:
– Clinical evidence of a painful heel spur
– Radiological proof of the spur (plain lateral
radiographs of the heel)
– Duration of anamnesis more than six months
– Karnofsky performance status > =70 %
– Age > = 40 years.
Patients showing
– Previous radiation therapy to the foot
– Previous trauma to the foot
– Rheumatic, arterial or venous diseases, or manifest
lymphatic edema of the concerned foot/leg
– Pregnancy or breastfeeding
– Severe psychiatric disorders
were considered ineligible for this trial.
Patients with a long duration of anamnesis and refrac-
tory to former treatments could be enrolled. The use of
analgesics before and after enrolment was not limited.
Patients having undergone surgery or shock wave ther-
apy after randomization were excluded.
All patients gave their written informed consent to radi-
ation therapy and to participate in this trial before enrol-
ment. They were randomly assigned by the statistician
(G.S.) to one of the following groups:
– Standard dose group: total dose of 6 Gy applied in
single fractions of 1Gy twice a week
– Experimental dose group: total dose of 6Gy applied
in single fractions of 0.5 Gy three times a week.
Radiotherapy sessions were performed on Monday/
Thursday or Tuesday/Friday (standard dose group) and
on Monday/Wednesday/Friday (experimental dose group)
to avoid treatment sessions on consecutive days.
Follow-up examinations were scheduled every six weeks
either by an examination of the patient in the clinic or by
mailing questionnaires to the patients. All patients are
intended to receive a follow-up for 48 weeks. The duration
of follow-up was chosen on the basis of our retrospective
experience that the vast majority of beneficial effects be-
came apparent after less than one year.
Primary endpoints were
– SF12 sum score (high values = good quality of life) [13]
– Calcaneodynia pain sum score (100 = free of
symptoms, 0 = very intense symptoms) [14, 2]
– Visual analogue scale (0 = no pain, 100 = maximum
imaginable pain intensity)
Secondary endpoints were the SF12 single scores,
Calcaneodynia single scores and the event-free interval.
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Radiation therapy was performed using 6 MV- pho-
tons of a linear accelerator applying lateral opposing
portals. The calcaneus and the plantar aponeurosis were
included in the target volume. The dose was prescribed
to the ICRU reference point in the center of the calca-
neus. The dose was calculated individually according to
the clinician’s measurements.
The trial protocol was approved by the Ethics commit-
tee of the Saarland Physicians’ Chamber (number 14/07
on 09/05/2012). Furthermore, it has been approved by
the expert committee of the DEGRO (German Society
for Radiation Oncology). The research carried out here
is in compliance with the Declaration of Helsinki in its
current version.
Randomization was performed as a block randomization
by the statistician. Patients were assigned randomly to one
of the therapy arms by equal possibility for randomization
for both arms.
According to a previous trial published by Niewald
et al. [15, 5] 120 patients are required in each arm and
have to be evaluated over 48 weeks (inclusive a drop-out
rate of 10 % of the patients) in order to detect a differ-
ence of 15 % in VAS and Calcaneodynia-scores with a
power of 80 % (error probability of 5 %).
The categorical variables (patients’ demographic and
disease data (see Table 1) were compared using the
chi-square test and Fisher’s exact test, respectively.
Because they were not normally distributed, the pain
and quality of life scores in the groups were compared
using the Mann–Whitney-U-test (see Tables 2 and
3). P-values < =0.05 were considered as statistically
significant.
The statistical computations were performed using the
MEDLOG software package (Fa. Parox, Münster) after
observing the patients for 12 weeks and were controlled
by the statistician. Further details of this trial protocol
have been published elsewhere [5].
Results
A total of 127 patients were included in this trial. A major-
ity of 112 patients was treated in the University Hospital
of Homburg, ten in the University Hospital of Regensburg,
and the remaining five in the University Hospital of
Mainz.
Nine patients had to be excluded after randomization
either due to their refusal to undergo therapy or to radio-
therapy with an incorrect dosage (that of the other arm).
A further patient was excluded due to a critical lack of
data. Finally, 59 patients were assigned to the standard
dose group and the remaining 58 to the experimental dose
group. Of those, 54 patients in the standard dose group
and 53 in the experimental dose group could be followed-
up for twelve weeks.
Comparison of patient groups
The mean age at enrolment was 56.1 years (standard
dose group) and 58.1 years (experimental dose group,
p = 0.207). The mean duration of pain anamnesis was
17 (standard dose group) vs. 16 months (experimental
dose group, p = 0.882). Concerning localization of spur,
extension and start of pain, impact on quality of life,
daily work and sports, and former therapy we did not
find any significant differences between the groups. A
significant imbalance was noticed concerning the
localization of pain (p = 0.004). Details are summarized
in Table 1.
The VAS scores before radiation therapy were distrib-
uted equally between the groups (p = 0.069) whereas the
Calcaneodynia pain score (CS) was found incomparable
(p = 0.002) with a mean value of 41.9 in the standard
dose group and of 47.5 in the experimental dose group
indicating a slightly worse pain situation in the standard
dose group. There were no statistically significant different
values between the groups concerning the SF 12 results
(psychic and somatic problems, patient’s and doctor’s
evaluation). The detailed data are summarized in Table 2.
Results after three months’ follow-up
The mean difference of the VAS scores after three
months compared to the values before radiation therapy
was 42.3 in the standard dose group and 44.4 in the ex-
perimental dose group (p = 0.778). A similar result was
found when evaluating the CS score (p = 0.779). Conse-
quently, no statistically significant difference could be
found between the groups.
The results concerning quality of life fitted well to
those concerning pain. No statistically significant differ-
ences could be found (somatic scale, doctor’s judgement:
p = 0.321; psychic scale, doctor’s judgement: p = 0.662;
somatic scale, patient’s judgement: p = 0.559; psychic scale,
patient’s judgement: p = 0.952).
No relevant side effects were recorded.
Discussion
The aim of this multicenter randomized study was to
compare the analgesic effect of standard single doses
compared to lower ones keeping the total dose constant.
At the time this trial was planned, the standard dose was
1.0Gy twice a week up to a total dose of 6Gy. Compared
to this dosage we did not find any difference in our ex-
perimental arm (12 times 0.5Gy three times a week). In
the meantime, a new standard of single doses or 0.5Gy
twice a week up to a total dose of 3.0Gy has been estab-
lished according to the results published by Heyd et al.
[16] and Ott et al. [17]. Compared to this standard we
did not see any benefit after escalation of the dose to
6Gy. In summary, we could not find any difference
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SD 9.2 8.7 0.207
(t-Test)
Localization of spur
Plantar 58 (98 %) 54 (93 %)
Plantar and dorsal 1 (2 %) 4 (7 %) 0.350





Right = left 5 (7 %)
Right > left 5 (8 %) 2 (3 %)
Left > right 9 (16 %) 1 (2 %)
Right only 26 (44 %) 22 (38 %)
Left only 19 (32 %) 29 (50 %) 0.004
Extension of pain
None 21 (36 %) 20 (34 %)
Calf 15 (25 %) 17 (29 %)
Sole of foot 16 (27 %) 15 (26 %)
both 7 (12 %) 6 (11 %) 0.979
Start of pain
Not known 2 (3 %) 1 (2 %)
Suddenly 23 (39 %) 24 (41 %)
Insidious 34 (58 %) 33 (57 %) >0.999
Impact of pain on life
quality
No impact 3 (5 %)
Leisure 4 (7 %) 7 (12 %)
Work 3 (5 %) 1 (2 %)
Leisure and work 52 (88 %) 47 (81 %) 0.165
Effects on daily work
Able to work 49 (83 %) 52 (90 %)
Unable to work 7 (12 %) 2 (3 %)
No occupancy 3 (5 %) 4 (7 %) 0.258
Effects on leisure/
sports
Unlimited 1 (2 %) 3 (5 %)
Limited 40 (68 %) 37 (64 %)
Impossible 16 (27 %) 17 (29 %)
No sports 2 (3 %) 1 (3 %) 0.722
Former therapy using
Ice/heat 7 (12 %) 3 (5 %) 0.322
Ultrasound 8 (14 %) 15 (26 %) 0.108
Table 1 Comparison of patient data (Continued)
Microwaves 1 (2 %) 1 (2 %) >0.999
Oral medication 36 (61 %) 39 (67 %) 0.564
Injections 19 (32 %) 23 (40 %) 0.444
Heel splints 56 (95 %) 55 (95 %) >0.999
Other
shoe adjustment
4 (7 %) 4 (7 %) >0.999











































CS calcaneodynia score, VAS visual analogue scale, SD standard deviation
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resulting in the assumption that the in-vivo results could
not be translated into clinical pain relief.
The authors are well aware of the limitations of this
trial. Because of the results of the interim analysis shown
here without a reasonable probability to see a significant
difference between the groups by recruiting further pa-
tients the study was closed prematurely which may limit
its statistical power. A further reason for the early clos-
ure were the results published by Ott et al. [17] showing
that the same grade and duration of pain relief can be
achieved applying a total dose of 3 Gy in single fractions
of 0.5 Gy twice a week compared to the known standard
dose of 6 Gy in single fractions of 1.0 Gy twice a week at
a high level of evidence. In the meantime, the standard
total dosage has been lowered to 3 Gy in many institu-
tions in Germany according to the ALARA principle
(keep the dose as low as reasonably achievable). Thus,
continuation of the trial could have lead to an ethical
problem.
Furthermore, the trial was conducted in a randomized
manner but not blinded to the patient or the physician.
Using a linear accelerator, it seemed nearly impossible
and unethical to perform a blinded radiotherapy. Finally,
the results may have been confounded by the fact that
concomitant therapy with oral analgesics was not lim-
ited. Otherwise, it may be assumed that limitation of
concomitant medication would have caused an un-
wanted selection bias.
Numerous retrospective trials have shown that low-
dose radiotherapy for painful heel spur has a good anal-
gesic effect, pain relief has been noticed in 65 – 90 % of
the patients (literature table in [18]). However, a certain
placebo effect is still under discussion [19]. Goldie et al.
examined this effect in 399 patients. They found a re-
sponse in 60 % of the patients whether irradiated or not;
these results made the effect of radiotherapy question-
able [20]. The trial, however, has been criticized because
of missing clearly defined endpoints: furthermore the
therapy was started in an acute stage of the diseases and
the authors did not wait for spontaneous pain remis-
sions. In the meantime, several more modern trials have
shown the analgesic effect of radiotherapy. Seegen-
schmiedt et al. [3] performed a randomized trial treating
141 patients (170 heels) for painful heel spur using
orthovoltage, comparing three radiotherapy schedules:
1 Gy/fraction up to 12 Gy, 0.3 Gy/fraction up to 3 Gy
and 0.5 Gy/fraction up to 5 Gy. The overall complete
pain relief was reported in 67–72 % of the patients. The
best results were seen after a total dose of 5 Gy. These
results were confirmed by Schäfer et al. using a teleco-
balt machine, they achieved a complete pain relief in
58 % [33]. Heyd et al. used 6 MV photon beams of a lin-
ear accelerator, they noticed a frequency of pain relief of
69 % [4]. The same author group published a prospect-
ive randomized trial recently [16] comparing the effect
of a total dose of 3 Gy (single fraction 0.5 Gy twice a
week) to that of a total dose of 6 Gy (single fraction
1 Gy twice a week). Radiotherapy was reported very effi-
cient, however a dependency on dose could not be
Table 3 Comparison of pain/quality of life data 12 weeks after














































Maximum 18 17 0.952
p
VAS(0), CS(0), SF12(0): values before start of radiation therapy
VAS(12), CS(12), SF12(12): values after 12 weeks’ follow-up
VAS scale: linear scale, 0 = no pain, 100 =maximum imaginable pain,
improvement = negative difference, worsening = positive difference
CS scale: linear scale based on criteria like pain, use of aids, problems at work,
in daily life, and performing sports, gait: 0 = maximum pain and disability,
100 = complete freedom from symptoms; improvement = positive difference,
worsening = negative difference
SF12 scales: complex scales using 12 items on quality of life; high values = favorable
quality of life; improvement = positive difference, worsening = negative difference
SD standard deviation
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noticed. Mücke et al. looked for prognostic factors for
pain relief in a multicenter trial [18]. They found an
overall response in 60.9 %. Significant favourable prog-
nostic factors for pain relief were a patient's age over
58 years, the use of megavoltage techniques and the
number of therapy series required. Niewald et al. showed
in a recent prospective study that a total dose of 6 Gy
with single doses of 1 Gy twice a week is much more ef-
fective than a total dose of 0.6 Gy with single doses of
0.1 Gy twice a week concerning analgesic effect and
showed that a total doses of 6 Gy makes this effect dur-
able for at least 1 year [5]. The important results pub-
lished by Ott et al. [17] have been mentioned earlier.
Conclusions
Radiation therapy yields important pain relief in patients
with painful heel spur (plantar fasciitis). The very en-
couraging laboratory results showing an enhanced effect
of single doses in the range of 0.5-0.7 Gy compared to
higher ones could not be translated into clinical practice.
Until now we found no plausible explanation for this re-
sult. Further trials based on a total dose of 3 Gy will be
necessary to explore the best dose schedule. This trial
will be continued until all patients have reached a
follow-up duration of 48 weeks. Only these long-term
results will allow a final decision.
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